Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Viracta Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Viracta Therapeutics, Inc.

VIRX

Viracta Therapeutics, Inc.

About Viracta Therapeutics, Inc.

Viracta Therapeutics is a clinical-stage biotech focused on developing targeted therapies for virus-associated cancers, especially EBV-related malignancies. Its lead product combines epigenetic and antiviral agents to treat lymphomas and solid tumors. The company leverages its proprietary Kick and Kill approach, targeting viral genomes to induce tumor cell death, with a focus on unmet medical needs in oncology markets worldwide.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Viracta Therapeutics, Inc.

1
1
Viracta Therapeutics, Inc. Viracta Therapeutics Reports Financial Developments, Seeks Additional Funding Amid Ongoing Net Losses

Via official filing (AI summary) | over 1 year ago | 0 comments